Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 in traumatic brain injury with neurobehavioral disinhibition
NCT03095066Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2017
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deudextromethorphan in Neurobehavioral disinhibition (8 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Neuropsychiatric Inventory Clinician Rating Scale Composite of Aggression, Agitation, and Irritability/Lability at 12 weeks. Started May 2017; status: completed.
02
Drugs
deudextromethorphan
03
Conditions
Neurobehavioral disinhibition
Beyond the preview
Go deeper on NCT03095066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095066.